Daniel Cohen is a Managing Director at Morgan Stanley, where he serves as Global Head of Pharma Outsourcing Investment Banking. He is responsible for managing the firm’s relationships with various CDMOs, CROs, pharmaceutical and other companies across the pharmaceutical supply chain ecosystem.

He is an accomplished investment banker, having worked with and advised companies over the past 25+ years on M&A, equity, and debt financing transactions. Prior to joining Morgan Stanley, Mr. Cohen served as Head of Healthcare Services Investment Banking at Truist Securities and RBC Capital Markets.

Previously, Mr. Cohen was a member of the Executive Leadership Team and head of Global Corporate Development at Catalent. He joined Catalent in 2010 and was responsible for developing and overseeing execution of Catalent’s inorganic growth strategy. Mr. Cohen’s transaction experience at Catalent included acquisitions, divestitures, structured transactions in the US, Europe, Latin America and Asia, completing 14 transactions valued at approximately $1 billion. Prior to Catalent, Mr. Cohen spent 13 years on Wall Street, where he focused on healthcare M&A, particularly within the drug delivery,  specialty pharma and generic pharma industries, including at over a decade at Bear Stearns.

Sessions

Pharma Industry Outlook